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As agreed before, I would like to submit our manuscript entitled “Multifunctional
Nanohybrid Based on Porous Silicon Nanoparticles, Gold Nanoparticles and
Acetalated Dextran for Efficient Liver Regeneration and Acute Liver Failure
Theranostics” by Zehua Liu, Yunzhan Li, Dr. Wei Li, Chen Xiao, Dr. Dongfei Liu, Chao
Dong, Ming Zhang, Ermei Mäkilä, Dr. Marianna Kemell, Prof. Jarno Salonen, Prof.
Jouni T. Hirvonen, Prof. Hongbo Zhang, Prof. Dawang Zhou, Prof. Xianming Deng, and
Prof. Hélder A. Santos, for the Special issue ‘Materials Science in Finland’ for
publication as a Communication in Advanced Materials.
One of the major aims in nanomedicine is the ability to perform multiple functions using
the same nanocarrier, that is, the ability to target, image, diagnose and monitor disease
progress using only one single nanoparticle, which is also currently under investigation
for applications in hepatopathy diagnose and therapy. Moreover, nanoparticles with
specific optical or imaging properties can improve the detection of different liver
diseases and play an important role in therapeutic decision-making.
Acute liver failure (ALF) is a clinical syndrome as a result of the rapid loss in
hepatocyte functions. Due to the limited therapeutically possibilities and the lack of
diagnosis/imaging methods, ALF patients represent some of the most challenging
cases in terms of the level and complexity of care required.
Among all the proposed biomaterials so far, porous silicon nanoparticles (PSi NPs)
have been widely investigated as advanced biomaterial as it is biodegradable and
biocompatible with tunable pore sizes and has a versatile surface physicochemical
properties, making PSi very flexible in loading different kind of cargos for anti-cancer,
diabetes, heart infraction and immunotherapy.
The unique physical and optical properties of gold nanoparticles (Au NPs) have led to
various schemes for developing Au NPs as a contrast-enhancing agent for computer
tomography (CT), Raman, X-ray and photoacoustic imaging applications. Several
papers have demonstrated the feasibility of applying CT imaging to track monocyte
recruitment to tissue plaques using Au NPs as contrasting agent, and the contrasting
efficiency of Au NPs is largely related with its particle size: Too small Au NPs ( 150
nm), despite their satisfied MPS uptake and contrasting ability, can hardly be excreted
from the body and show higher cellular toxicity. To address this obstacle, it is desirable
that the initial size of Au NPs is relatively small with high biocompatibility, and further
be incorporated into a larger biodegradable/biocompatible matrix to reduce renal
clearance and improve macrophages uptake. Once the NPs are uptaken by the MPS,
which is accumulated within the plaque sites, the matrix will collapsing to release the
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Au NPs.
Upon such consideration, we hypothesize the construction of a PSi/Au nanohybrid has
highly potential to be applied into liver regeneration and ALF theranostics. But in order
to achieve this, we need to further establish one facile, versatile method to efficiently
encapsulate both particles within one single carrier at the same time. Herein, we report
a novel nanohybrid-based on PSi, Au NPs and acetalated dextran
(DPSi/DAu@AcDEX) to effectively encapsulate and deliver one drug and increase the
CT signal for ALF theranostics, using a microfluidic-assisted single-step co-
encapsulating of different nanoparticles at the same time. By alternating the surface
properties of different nanoparticles and by modulating the composition of the organic
phase, we effectively encapsulated both PSi and Au NPs into the polymer matrix
simultaneously, thus further achieving a multifunctional application.
In summary, we have successfully prepared a PSi-based nanohybrid composite for
liver regeneration and ALF treatment. This system can be used to identify
pathologically changes in the tissues and selectively deliver drugs to these sites, which
have an extremely high potential to ameliorate therapeutic outcomes for patients. It
also effectively loads the therapeutic compound (XMU-MP-1) inside, which greatly
improves the drug solubility, precise in situ drug delivery and the drug functioning time.
In vivo results confirmed the superior treatment effect and better compliance of this
newly developed nanoformulation than free compound. Considering our data, the
application of our nanosystem appears to play a crucial role in targeting the lesion
area, thus an increased local drug concentration may attribute to the improved ALF
reverse effect. Moreover, the residence of Au particles within the matrix further endows
our system for CT-imaging, which shows promise to diagnose ALF at an early stage.
Altogether, these results support that the developed nanohybrid has a potential
theranostic platform for ALF.
This work brings together several scientific areas, including materials science,
biomedical engineering, biomaterials, drug delivery, and bio-imaging by NPs. This new
result is completely covered within the scope of Advanced Materials and is of timely
interest to the readers of this journal. We firmly believe that this manuscript is suitable
for publishing in Advanced Materials.
We truly declare that the present article and its contents have not been previously
published in any language anywhere by any of the present authors and are not also
under simultaneous consideration in another journal at the time of this submission.
Thank you for your consideration.
Sincerely yours,
Hélder Santos
Associate Professor Dr. Hélder A. Santos, D.Sc. (Chem. Eng.)
Head of the Pharmaceutical Nanotechnology and Chemical Microsystems Unit
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Abstract: Herein, we report a novel nanohybrid-based on porous silicon, gold NPs and
acetalated dextran(DPSi/DAu@AcDEX) to effectively encapsulate and deliver one drug
and increase the CT signal for acute liver failure(ALF) theranostics. Microfluidic-
assisted method is used to encapsulate NPs into a polymer matrix, using a single-step
co-encapsulating of different NPs at the same time. By alternating the surface
properties of different NPs and by modulating the composition of the organic phase, we
effectively encapsulated both PSi and Au NPs into the polymer matrix simultaneously,
thus further achieving a multifunctional application. This system can be used to identify
pathologically changes in the tissues and selectively deliver drugs to these sites. It also
effectively loads the therapeutic compound(XMU-MP-1) inside, improving the drug
solubility, precise in situ drug delivery and the drug functioning time. In vivo results
confirmed the superior treatment effect and better compliance of this newly developed
nanoformulation than free compound. This nanosystem plays a crucial role in targeting
the lesion area, thus increasing the local drug concentration important for ALF reverse
effect. Moreover, the residence of Au NPs within the matrix further endows our system
for CT-imaging. Altogether, these results support that this nanohybrid has a potential
theranostic platform for ALF.
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One of the major aims in nanomedicine is the ability to perform multiple functions using the 
same nanocarrier, that is, the ability to target, image, diagnose and monitor disease progress 
using only one single nanoparticle, which is also currently under investigation for applications 
in hepatopathy diagnose and therapy.[1, 2] A large variety of drugs can be associated to 
nanocarriers to enable liver-targeted drug delivery. Compared with other methods, the 
treatment plan involving the use of multifunctional nanoparticles holds the promise of more 
accurately targeted treatment, with a higher likelihood of a successful outcome.[3-5] Moreover, 
nanoparticles with specific optical or imaging properties, such as gold nanoparticles[3], iron 
oxides[6], and alkaline earth metal-based nanoparticles[7] can improve the detection of 
different liver diseases and play an important role in therapeutic decision-making.  
Acute liver failure (ALF) is a clinical syndrome as a result of the rapid loss in hepatocyte 
functions. Due to the limited therapeutically possibilities and the lack of diagnosis/imaging 
methods, ALF patients represent some of the most challenging cases in terms of the level and 
complexity of care required.[8] Despite the recently promising results brought by the newly 
developed small molecules, the lack of a proper drug delivery method may greatly impact 
their further application and the inherent limitation of conventional imaging methods for ALF 
makes the treatment process monitoring very difficult.[9] Therefore, a novel nanohybrid-based 
theranostic platform is urgently needed to solve the aforementioned problems. 
Among all the proposed biomaterials so far, porous silicon nanoparticles (PSi NPs) have been 
widely investigated as advanced biomaterial as it is biodegradable and biocompatible with 
tunable pore sizes and has a versatile surface physicochemical properties, making PSi very 
flexible in loading different kind of cargos for anti-cancer, diabetes, heart infraction and 
immunotherapy.[10-15] Moreover, within the hepatopathy care, PSi is unique from other 
biomaterials as recent reports showed the administration of extra silicon, which is the main 





































































the PSi drug delivery system very attractive for hepatopathy drug delivery, yet only very few 
attempts have been made to apply PSi into hepatic diseases and liver regeneration.[18] 
Former clinical studies suggested abdominal computer tomography (CT) scanning can play a 
useful role in the management of patients with ALF,[19] and the unique physical and optical 
properties of gold nanoparticles (Au NPs) have led to various schemes for developing Au NPs 
as a contrast-enhancing agent for CT, Raman, X-ray and photoacoustic imaging 
applications.[20] The high atomic number and electron density of Au makes it a good candidate 
for CT imaging,[21] hence applying Au NPs based nanohybrids is highly potent for hepatic 
disease theranostics. Several papers have demonstrated the feasibility of applying CT imaging 
to track monocyte recruitment to tissue plaques using Au NPs as contrasting agent,[22, 23] and 
the contrasting efficiency of Au NPs is largely related with its particle size: Too small Au NPs 
(< 5nm) suffer from rapid clearance by renal filtration, leading to low plaque accumulation, 
and they also tend to show limited monocyte phagocytic system (MPS) uptake, resulting in an 
unsatisfied lesion tracking ability; whereas larger Au NPs (> 150 nm), despite their satisfied 
MPS uptake and contrasting ability, can hardly be excreted from the body and show higher 
cellular toxicity.[24] To address this obstacle, it is desirable that the initial size of Au NPs is 
relatively small with high biocompatibility, and further be incorporated into a larger 
biodegradable/biocompatible matrix to reduce renal clearance and improve macrophages 
uptake. Once the NPs are taken up by the MPS, which are accumulated within the plaque sites, 
the polymer matrix will collapse to release the Au NPs.[25, 26] 
Upon such consideration, we hypothesize the construction of a PSi/Au nanohybrid has highly 
potential to be applied into liver regeneration and ALF theranostics. But in order to achieve 
this, we need to further establish one facile, versatile method to efficiently encapsulate both 
particles within one single carrier at the same time. Herein, we report a novel nanohybrid-
based on PSi, Au NPs and acetalated dextran (DPSi/DAu@AcDEX) to effectively 





































































studies used microfluidic-assisted methods to encapsulate nanoparticles into a polymer matrix, 
yet there are few papers demonstrating a single-step co-encapsulating of different 
nanoparticles at the same time.[27, 28] In this study, by alternating the surface properties of 
different nanoparticles and by modulating the composition of the organic phase, we 
effectively encapsulate both PSi and Au NPs into the polymer matrix simultaneously, thus 
further achieving a multifunctional application.  
Facilitated by the application of PSi, XMU-MP-1, a recently developed small molecule with 
the promising potential for ALF treatment (Figure S1A),[9] is effectively loaded inside the 
nanohybrid. To solve the major obstacle that ALF lacks of bio-imaging based diagnose tool, 
dextranylated gold nanoparticles (DAu NPs) are constructed and simultaneously entrapped 
into the polymer matrix alone with dextranylated PSi (DPSi). By constructing this 
DPSi/DAu@AcDEX nanostructure, our nanohybrids also have the ability to act as a 
contrasting agent for CT-imaging. Acetalated dextran (AcDEX), a biologically safe and pH-
sensitive polymer, is used to form the outer polymer matrix. AcDEX is widely applied in 
tissue engineering, controlled drug delivery and immunomodulation for multiple reasons.[29] 
The introduction of outer AcDEX matrix can block the pores of PSi for the drug release, but 
the decomposition of AcDEX under acidic environment allows the intracellular drug release 
and the dormant Au NPs release, thus the size dilemma of Au NPs within plaque detection is 
also solved by this hierarchical strategy. Most importantly, this facile method to encapsulate 
different particles within one polymer matrix offers the possibilities to construct different kind 
of multifunctional nanohybrids. As far as we know, this is the first time investigating PSi as 
drug delivery system for liver regeneration and further evaluating its potent application in 
ALF therapy. 
The approach for the construction of DPSi/DAu@AcDEX is illustrated in Figure 1A. We 
used a well-established method to synthesize AcDEX and its derivate spermine AcDEX,[30, 31] 





































































Supporting Information) spectrum. Undecylenic acid-modified thermally hydrocarbonized 
PSi was applied because the hydrophobic surface favors the loading of XMU-MP-1. The PSi 
particles were modified by spermine AcDEX to form DPSi (Figure 1B(a)); the introduction 
of spermine AcDEX can both increase its dispersity and biocompatibility and also facilitate 
the nucleation process to further construct the nanohybrid. Similarly, Au NPs were modified 
with spermine AcDEX to form DAu (Figure 1B(b)). The successful modification of DPSi 
and DAu was confirmed by Fourier transform infrared spectroscopy (FTIR) and NMR 
(Figure 1C, Figure S2). Microfluidics assisted nanoprecipitation method was carried out to 
construct DPSi/DAu@AcDEX, and the nanoprecipitation process was triggered by passive 
microfluidic mixing in a co-flow capillary microtube. The outer AcDEX layer within the 
microtube was formed through nucleation and nano-precipitation driven by diffusion and 
mixing between the solvent (ethanol/acetonitrile = 9:1, v/v) and anti-solvent (1% Poloxamer 
188 water solution) streams across the interface. We previously found out that size has an 
important role in AcDEX encapsulation.[27] To encapsulate DPSi with a size around 200 nm, 
we optimized the size of bare AcDEX particles and 300 nm spherical AcDEX particles were 
applied in the following (Figure 1B(c)) encapsulation process of DPSi. Transmission electron 
microscopy (TEM) images indicated the successful encapsulation of PSi nanoparticles in the 
AcDEX matrix. As it can be seen in Figure 1B(d), after encapsulation, the irregular shape 
and the porous structure of DPSi were fully covered and new nanohybrids with spherical 
morphology were formed. Energy dispersive X-ray microscopy (EDX) was carried out to 
further confirm the DPSi inside the AcDEX particle, where the clear peak of Si indicated the 
presence of DPSi. After the encapsulation, size changes from 207±10 (DPSi) to 332±3 nm 
(polydispersity index (PdI): 0.19±0.01 vs. 0.11±0.02) were detected and also the zeta (ζ)-
potential values were shifted from +6.2 ± 1.0 to –31.4 ± 4.0 mV due to the fact that the amine 
groups on DPSi were covered by AcDEX. We further encapsulated DAu together with DPSi. 





































































modified Au NPs (dodecane conjugated) tend not to accumulate in the polymer matrix but to 
disperse within the medium (Figure S3A). After adding DAu inside the nanohybrids, both the 
sphericalness and the morphology of the nanohybrids showed no significant differences. EDX 
spectrum confirmed the co-existence of both DPSi and DAu inside AcDEX matrix, as clear 
Au and Si signals could be observed simultaneously in the same particle (Figure 1B(e,f)). 
The size of the final DPSi/DAu@AcDEX composite was increased to 473 ± 13 nm comparing 
to 332 nm for DPSi@AcDEX, whereas the ζ-potential values did not have clear changes (–
33.2 ± 0.7 mV), which partially suggests that the DAu (+ 11.5 ± 1.9 mV) was more likely to 
be encapsulated inside the polymer matrix (Figure 1C). FTIR results also partially confirmed 
the successful encapsulation of DPSi as well as DAu (Figure 1D). After the modification of 
PSi, the DPSi spectrum showed a decrease in the band at 1720 cm-1, which is the typical band 
for carboxyl, and a new band at 1530 cm-1 was observed due to the formation of amide bonds. 
After the AcDEX encapsulation the typical band from DPSi disappeared and was replaced by 
the bands from AcDEX. This is different from simple physical mixture, wherein the typical 
carboxyl band from DPSi (1720 cm-1) is still visible (Figure S3). To evaluate whether the 
surface modification and drug loading affected the encapsulation process, we used different 
surface functionalized DPSi to construct the same structure, and the results showed that 
neither the conjugation of the fluorescence dye (Alexa Fluor® 488, Figure S4B), conjugation 
of peptide (R8 cell penetration peptide, Figure S4C), nor the loading of the drug (Figure 
S4D,E) affected the formation of the nanohybrids. Most importantly, even at the different 
PSi/Au ratios, similar nanostructures could be constructed (DPSi/DAu = 1:5, w/w, Figure 
1B(f), DPSi/DAu = 1:1, w/w, Figure S4F) without obvious free Au NPs within the medium. 










































































































































Figure 1. Preparation and Characterization of DPSi/DAu@AcDEX. (A) Schematic 
illustration of the procedure to prepare the DPSi/DAu@AcDEX by microfluidics. (B) TEM 
images showing morphologies of (a) DPSi, (b) DAu, (c) AcDEX template particle, (d) 
DPSi@AcDEX, (e,f) DPSi/DAu@AcDEX at each step and the corresponding EDX spectrum. 
(C) Size (nm), PdI and surface zeta potentials (mV) values at each synthesis step. (D) FTIR 
spectra of PSi, DPSi, AcDEX, DPSi@AcDEX and DPSi/DAu@AcDEX, suggesting the 
encapsulation process. 
 
We further investigated the drug loading and releasing profile of XMU-MP-1 loaded 
DPSi/DAu@AcDEX (MP@DPSi/DAu@AcDEX) in vitro. XMU-MP-1 is a highly insoluble 
drug in different solvents and it is very difficult to be administered (Table S1). PSi has been 
showed to have the ability to improve the in vivo drug bioavailability, especially for 
hydrophobic drug.[32] Without the application of DPSi, by using the same drug encapsulation 
procedure, the drug loading degree within the AcDEX matrix is as low as 0.04%. With DPSi, 
we achieved a final loading degree of 7.8% for XMU-MP-1 within the nanohybrid. Due to the 
coverage of AcDEX layer, the drug loaded inside the DPSi is hardly released at the 
physiological conditions, thus preventing the premature drug release. However, AcDEX 
slowly degrades at pH 7.4, thus we can detect insignificant XMU-MP-1 release after 24 h 
(Figure S5A). At pH 5.0, the AcDEX shell rapidly dissolved through decomposition of the 
acetal bonds and regenerating of the water-soluble dextran; and therefore, the pores were 
exposed to the outer solution and the drug was released (Figure 2A). Liver is a highly 
promising organ for nanocarrier-based targeting as it is the major accumulation place for 
nanoparticles.[33-35] Within the liver microarchitecture, blood flow is significantly slower than 
in the systemic circulation. The reduced velocity promotes preferential nanomaterial 





































































majority of the particles are taken up by the stationary Kupffer cells or internalized by the 
patrolling macrophages and further transfer to liver.[34-36] To better simulate this condition, we 
conducted cellular level drug release studies by co-incubating the particles and macrophages 
(KG1). Figure 2B shows that within the blank medium, few drug can be detected to be 
released from the particles, but when the KG1 cells were added, the drug released to the 
medium had a significant augment after 3 h. The rationale behind this is when the particle is 
internalized by the macrophages, the AcDEX matrix will degrade within endosomes and 
further release the drug, small molecule XMU-MP-1 with high permeability could penetrate 
through the membrane of KG1 and potentially reach to hepatocytes. 
We further investigated the potential of liver regeneration effect of our system in vitro. 
XMU-MP-1 effectively inhibits the Sterile 20–like kinases MST1 and MST2 (MST1/2) 
activities in a variety of cells.[9] MST1/2 inhibition leads to the dephosphorylation of MOB, 
the specific substrate of MST1/2, and further suppresses Yes-associated protein (YAP) 
phosphorylation, thereby activating the downstream effector YAP and promoting cell 
growth.[37, 38] Figure 2C demonstrates that our nanoformulation of XMU-MP-1 can potently 
inhibit MOB, and YAP phosphorylation in H2O2 treated cells. Comparing to free drug, our 
system presents a sustained functional behavior after 6 h. The proliferation effect was further 
tested on hepatocytes/macrophages co-culture model. Different hepatocytes/macrophages 
ratios were tested, and the hepatocytes/macrophages = 2/1 system was further used in the 
following experiments according to previous reports  (Figure S5B).[39]  
Two different administration methods were investigated separately to simulate different 
conditions. Due to favorable flow dynamics in liver, it has been demonstrated that the 
nanoparticles may accumulate within the liver architecture, then the cellular-bonded particles 
can remain on the cellular surface, or return to the circulation or be internalized through 
endocytosis or phagocytosis.[35] To simulate these conditions, we directly added XMU-MP-1 





































































h further incubation and test the viability of hepatocytes afterwards (co-culture model). The 
results showed a similar proliferation augment from the drug treatment (149 ± 9.9% and 143 
± 15.1%, free drug v.s. MP@DPSi/DAu@AcDEX at the highest concentration). To model the 
situation that DPSi/DAu@AcDEX will be recognized and be taken-up by the mononuclear 
phagocyte system (MPS) and further transported to the liver,[34] we first co-cultured different 
nanohybrid formulations with the macrophages for 4 h, then the pre-treated macrophages 
were collected and further co-incubated with hepatocytes for another 24 h (sequence-culture 
model). Comparing to free drug, significant high cell viability increase was observed for 
MP@DPSi/DAu@AcDEX at different concentrations (P < 0.05) (Figure 2D). Importantly, 
the viability augment of two different cell models treated with MP@DPSi/DAu@AcDEX had 
a similar trend, whereas for the free drug treated group, the sequence-culture model barely 
showed a proliferation effect. This confirms the effective cell proliferation augment of our 






































































Figure 2. (A) In vitro XMU-MP-1 release curves at pH 5 and pH 7.4 in phosphate buffer 
saline (PBS) containing 5% P-188 at 37 C within 5 h. (B) The XMU-MP-1 release curve at 
Roswell Park Memorial Institute (RPMI) medium containing KG1 macrophages at 37 C 
within 5 h. (C) Relative phosphorylation levels of MOB and YAP (p-MOB and p-YAP) in 
HepG2 were probed at various concentrations of XMU-MP-1 with different formulation 
treatments over time (1.5 to 12 h). The corresponding pannels (from left to right) are: control, 
dimethyl sulfoxide (DMSO)–treated control, H2O2-treated control, DPSi/DAu@AcDEX with 
low, medium and high concentration (from left to right), free XMU-MP-1 (1, 3, and 10 μM 
from left to right, dissolved in DMSO), and MP@DPSi/DAu@AcDEX (containing the same 
amount of XMU-MP-1 at the corresponding concentration). (D) Cell viability of HepG2 cells 





































































model for 24 h and (b) incubation of different formulations of XMU-MP-1 with KG1 for 4 h 
followed by harvesting the pre-treated KG1 cells and continuing the HepG2/KG1 co-culture 
model for 24 h. All the data sets were compared with the respective control. The 
concentration indicates the amount of DPSi/DAu@AcDEX. Data are shown as mean ± SD (n 
≥ 3), *P < 0.05 and **P < 0.01. 
 
Following the promising results in vitro, we moved to in vivo studies. Phosphorylation 
levels of key proteins MOB and YAP (p-MOB and p-YAP) in lysates of livers from wild-type 
mice treated with different formulations of XMU-MP-1 over time were firstly evaluated. 
Figure 3A shows the effective suppression of p-MOB and p-YAP, and importantly our 
nanoformulation of XMU-MP-1 exhibited longer effecting time comparing with the free drug. 
We further tested the effect of our system on ALF mouse model. ALF model was established 
by the overdosed administration of acetaminophen (APAP), which is also a common cause of 
ALF worldwide.[40] After 2.5 h of the APAP gavage, XMU-MP-1 was administrated 
intravenously (i.v.) in different nanoformulations at different concentrations twice daily 
(Figure 3B). Serum alanine aminotransferase (ALT) and aspartate transaminase (AST) levels 
were measured at different time points to study the hepatic function with robust reliability 
(Figure S6). After 12 h, the ALT levels with values of 2056 ± 326.7 vs. 36 ± 4.9 and the AST 
levels with values of 704 ± 124.6 vs. 36 ± 6.1 exhibited a boost increase comparing to healthy 
mice and macroscopic lesion parts were observed after 24 h (Figure S7), suggesting the 
successful establishment of the ALF model. After 12 h, XMU-MP-1 treatment can alleviate 
the damage in a dose-dependent manner. However, free drug at both doses of 0.1 mg kg-1 and 
0.5 mg kg-1 did not present a significant difference with ALF control group, whereas for the 
MP@DPSi/DAu@AcDEX, both concentrations showed a significant decrease of ALT and 





































































time extended to 24 h, ALT/AST levels in mice treated with MP@DPSi/DAu@AcDEX was 
markedly lower than free drug at both low dosage (890 ± 208.9 vs. 99 ± 29.9 for ALT, P < 
0.01 and 318 ± 82.7 vs. 103 ± 16.8 for AST, P < 0.05) and high dosage (328 ± 79.0 vs. 52 ± 
27.7 for ALT, P < 0.05 and 298 ± 66.7 vs. 127 ± 19.0 for AST, P < 0.05), indicating the 
superior improvement of therapeutic efficacy over free drug (Figure 3C(b)). Hematoxylin-
eosin (H&E) staining (Figure S8) and TdT-mediated dUTP Nick-End labeling (TUNEL) 
staining (Figure 3D) at the corresponding time points qualitatively indicated the ALF reverse 
and protection of liver damage by MP@DPSi/DAu@AcDEX to a remarkable extent in terms 
of lesion area, whereas free drug exhibited limited function. Furthermore, immunoblots 
results also suggest a better treatment effect from drug-loaded DPSi/DAu@AcDEX (Figure 
3E). At the time point of 72 h, despite the serological index showed similar liver recovery, 
from the TUNEL staining, mice treated with MP@DPSi/DAu@AcDEX had less scar 
structure, indicating a better rehabilitation (Figure 3C(c) and 3D). Moreover, at the drug dose 
of 3 mg kg-1 via i.v., mice mortality appeared when treated with free drug, which may be 
caused by the heart failure as a result of thrombus by drug precipitation. To confirm this, C-
X-C chemokine receptor type 4 (CXCR-4) immunohistochemical staining (Figure 3F) and 
TUNEL staining (Figure S9) heart sections at 72 h after administrating free drug or 
MP@DPSi/DAu@AcDEX were checked to reveal the potential cardiac damage. Comparing 
to the free drug group, no obvious myocardial infarction was observed after injecting 
MP@DPSi/DAu@AcDEX at the same dosage, which further demonstrates the enhanced 






































































Figure 3. (A) Immunoblots of p-MOB and p-YAP in lysates of livers from wild-type mice 





































































Schematics of drug evaluation in ALF model. (C) Serum ALT and AST levels at 12, 24, and 
72 h after APAP administration among wild-type mice, followed by intravenously injection of 
15% Solutol® HS 15 (control), free XMU-MP-1 (0.1 mg kg-1 as low concentration, 0.5 mg kg-
1 as high concentration, and free XMU-MP-1 is prepared by dissolving the drug into 15% 
Solutol® HS 15 at corresponding concentration), MP@DPSi/DAu@AcDEX (containing the 
same amount of XMU-MP-1 at low and high concentrations respectively), and blank 
DPSi/DAu@AcDEX at corresponding concentration. ALF model is established by 200 mg 
kg-1 APAP gavage administration. The treatment was initiated 2.5 h post APAP gavage. Drug 
is administrated twice daily for 3 days. Data are shown as mean ± SEM (n = 4); *P < 0.05 and 
**P < 0.01 (Student’s t-test). (D) TUNEL staining of liver sections at different time-points. 
ALF establish method and drug administration method are described above. All scale bars 
indicates 100 μm. (E) Immunoblots of p-MOB and p-YAP in lysates of livers from ALF mice 
treated with XMU-MP-1 (0.1 mg kg-1) with different formulations at 24 h post-ALF 
establishment. (F) CXCR-4 immunohistochemical staining heart sections at 72 h after 
administrating free drug or MP@DPSi/DAu@AcDEX (with 3 mg kg-1 of XMU-MP-1), 
suggesting the potential cardiac damage from the free drug administration. All scale bars 
indicate 100 μm. 
 
The potential rationale for the enhanced treatment index of MP@DPSi/DAu@AcDEX may 
be due to the lesion site specific accumulation of DPSi/DAu@AcDEX. It is well documented 
that following the occurrence of ALF, innate immune cells are recruited in a short time to the 
damage part to clear necrotic tissue and initiate the wound healing process.[41, 42] 
Immunofluorescence imaging demonstrates that for healthy mice macrophages were evenly 
distributed all over the liver, whereas for ALF mice the macrophages vastly concentrated at 





































































localization of our particles within the macrophages, and due to that our nanohybrids also 
accumulate within this specific region (Figure 4A). Figure 4B further confirmed the post-
ALF model establishment, a clear tendency of macrophages infiltration and enrichment was 
observed within necrotic plaque. So it is reasonable to assume the enhanced drug 
concentration within the damage area is induced by the increased local particles accumulation. 
In addition to that, due to the incorporated DAu within DPSi/DAu@AcDEX, we may apply 
the “Trojan horse” strategy into lesion detection and characterization. Early ALF lacks of 
proper bioimaging guided diagnostic method due to the initial damage may not induce 
detectable morphology changes in liver, thus introducing a proper contrasting agent is rather 
crucial.[43-45] Au NPs induce a strong X-ray attenuation and obsess unique physical, chemical, 
and biological properties, which make them an ideal candidate as CT-contrasting agents. In 
vitro CT images of aqueous dispersion of DPSi/DAu@AcDEX showed a DAu concentration 
dependent CT signal enhancement (Figure 4C). Due to the vast accumulation of macrophages 
within the lesion area and the major uptake of DPSi/DAu@AcDEX by macrophages, we 
expected to observe the lesion indication by CT-imaging. Figure 4D(a) showed no optical 
difference within ALF mice without the administration of DPSi/DAu@AcDEX, suggesting 
the limitation of conventional CT-imaging within ALF diagnosis. After i.v. injection of 
DPSi/DAu@AcDEX, for healthy mice, no clear signal was observed at a settled CT signal 
window (Figure 4D(b)). When defined the signal window to a relatively lower range, we 
observed that DAu are evenly distributed all over the liver (Figure S10). However, for ALF 
mice, a distinguishable area was generated by the accumulation of DPSi/DAu@AcDEX 30 
min post-injection. The rationale for the contrasting effect could be explained as after i.v. 
injecting the same amount of DPSi/DAu@AcDEX, normal liver has a decreased overall 
signal due to homogenous distribution of the particles as observed above, whereas damage 
will cause local accumulation of macrophages, which will enlarge the local signal as the 







































































Figure 4. (A) Immunofluorescence images of healthy liver or ALF liver after i.v. 
administrated with Alexa-488 labeled DPSi/DAu@AcDEX. All scale bars indicate 100 μm. 
(B) H&E staining of ALF liver, suggesting the lesion specific macrophages accumulation. All 
scale bars indicate 100 μm. (C) CT-images of the DPSi/DAu@AcDEX aqueous dispersion 
with different concentrations and CT value (HU) of DPSi/DAu@AcDEX at different 
concentration of DAu. (D) In vivo axial, coronal and sagittal CT images of ALF mice in 
absence of i.v. administration of DPSi/DAu@AcDEX, healthy mice after i.v. administration 





































































Healthy or ALF C57BL/6 mice after i.v. injected with 200 µL of DPSi/DAu@AcDEX at 20 
mg kg–1 of DAu. 
 
In summary, we have successfully prepared a PSi-based nanohybrid composite for liver 
regeneration and ALF treatment. This system can be used to identify pathologically changes 
in the tissues and selectively deliver drugs to these sites, which have an extremely high 
potential to ameliorate therapeutic outcomes for patients. It also effectively loads the 
therapeutic compound (XMU-MP-1) inside, which greatly improves the drug solubility, 
precise in situ drug delivery and the drug functioning time. In vivo results confirmed the 
superior treatment effect and better compliance of this newly developed nanoformulation than 
free compound. Considering our data, the application of our nanosystem appears to play a 
crucial role in targeting the lesion area, thus an increased local drug concentration may 
attribute to the improved ALF reverse effect. Moreover, the residence of Au particles within 
the matrix further endows our system for CT-imaging, which shows promise to diagnose ALF 
at an early stage. Altogether, these results support that the developed nanohybrid has a 
potential theranostic platform for ALF. 
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